Consilium MedicumConsilium Medicum2075-17532542-2170Consilium Medicum92287Research ArticleSovremennye podkhody k primeneniyu ingibitorov angiotenzinprevrashchayushchego fermenta dlya lecheniya serdechno-sosudistykh zabolevaniy (osnovnye polozheniya rekomendatsiy Evropeyskogo obshchestva kardiologov)BubnovaM. G-1511200681110110828122021Copyright © 2006, Consilium Medicum2006сердечно-сосудистые заболеванияингибиторы ангиотензинпревращающего ферментарекомендации[Expert consensus document on angiotensin converting enzyme inhibitors in cardiovascular disease. The Task Force on ACE-inhibitors of the European Society of Cardiоlogy. Eur Heart J 2004; 25: 1454-70.][Remme W.J, Swedberg K et al. for the task force for the diagnosis and treatment of chronic heart failure, European Society of Cardiology. Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J 2110; 22: 1527-60.][Report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure) ACC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult 2002. Available from: http://www.acc.org.][Mac Murray J, Cohen-Solal A, Dietz R et al. Practical recommendations for the use of ACE inhibitors, beta - blockers and spironolactone in heart failure: putting guidelines into practice Eur J Heart Failure 2001; 3: 495-502.][The Consensus Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. N Engl J Med 1987; 316: 1429-35.][The SOLD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325: 293-302.][Сohn J.N, Johnson G., Ziesche S et al. A comparison of enalapril with gydralazine - isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991; 325: 303-10.][Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infraction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy. Lancet 1993; 342: 821-8.][The SOLD Investigators. Effect of enalapril on mortality and development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1991; 327: 685-91.][Jong P, Yusuf S, Rousseau M.F et al. Effect of enalapril on 12 year survival and life expectancy in patients with left ventricular systolic dysfuction: a follow - up study. Lancet 2003; 361: 1843-48.][Pfeffer M.A, Braunwald E, Moye L.A et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfuction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 1992; 327: 669-77.][Kober L, Torp-Pedersen C, Carlsen J.E et al. for the trandolapril cardiac evaluation (TRACE) study group: a clinical trial of the angiotensin converting enzyme inhibitor trandolapril in patients with left ventricular dysfuction after myocardial infarction. N Engl J Med 1995; 33: 1670-6.][Torp-Pedersen C, Kober L. Effect of ACE inhibitor trandolapril on life expectancy of patients with reduced left - ventricular function after acute myocardial infarction. TRACE Study Group. Trandolapril Cardiac Evaluation. Lancet 1999; 354: 9-12.][Yusuf S, Pfeffer M.A, Swedberg K et al. for the CHARM Investigators and Committees. Effect of candesartan in patients with chronic heart failure and preserved left - ventricular ejection fractions: the CHARM Preserved Trial. Lancet 2003; 362: 777-81.][ACE inhibitor Myocardial Infarction Collaborative Group. Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100 000 patients in randomized trials. Circulation 1998; 97: 2202-12.][Flather M, Yusuf S, Kober L et al. for the ACE-inhibitor Myocardial Infarction Collaborative Group. Long - term ACE-inhibitor therapy in patients with heart failure or left - ventricular dysfunction: systematic overview of data from individual patients. Lancet 2000; 355: 1575-81.][The Heart Outcomes Prevention Evaluation Study Investigators (HOPE). Effect of angiotensin - converting - enzyme inhibitor, ramipril, on cardiovascular events in high - risk patients. N Engl J Med 2000; 342: 145-53.][The EURopean trial On reduction of cadiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomized, double - blind, placebo - controlled, multicentre trial (the EUROPA study). Lancet 2003; 362: 782-8.][Blood Pressure Lowering treatment Trialists Collaboration. Effects of ACE inhibitors, calcium antagonists, and other bloodpressure - lowering drugs: results of prospectively designed overviews of randomized trials. Lancet 2000; 355: 1955-64.][Staessen J.A, Wang J.G, Thijs L Cardiovascular protection and blood pressure reduction: a meta - analysis. Lancet 2001; 348 (7): 583-92.][Major outcomes in high - risk hypertensive patients randomized to angiotensin - converting - enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial. JAMA 2002; 36: 438-43.][Priori S.G, Aliot E, Blomstrom-Lundqvist C et al. for The Task Force on Sudden cardiac Death of the European Society of Cardiology. Update on the guidelines for sudden cardiac death of the European Society of Cardiology. Eur Heart J 2003; 24: 13-5.][Hornig B, Arakawa N, Hiussmann D et al. Differential effects of quinaprilat and enalaprilat n endothelial function of conduit arteries in patients with chronic heart failure. Circulation 1998; 22: 2842-9.][Mancini G.B.J, Henry G.C, Macaya C et al. Angiotensin - converting - enzyme inhibition with Quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND Study. Circulation 1996; 94: 258-65.][Schlaifer J.D, Mancini G.B.J, O'Neill B.J et al. The TREND Investigators. Influence of smoking status on angiotensin - converting enzyme inhibition - related improvement in coronary endothelial function. Cardiovasc Drugs Ther 1999; 13: 201-9.][Oosterga M, Voors A.A, Pinto Y.M et al. Effect of quinapril on clinical outcome ater coronary artery bypass grafting (The QUO VADIS Study) Am J Cardiol 2001; 87: 542-6]